Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Intern Med. 2010 Jul 6;153(1):8-18. doi: 10.7326/0003-4819-153-1-201007060-00004.

Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.

Collaborators (405)

Hull RD, Monreal M, Samama MM, Schellong SM, Tapson VF, Turpie AG, Yusen RD, Easton D, Haas S, Marder VJ, Meyer G, Wang YJ, Schellong SM, Halbritter K, Hull RD, Monreal M, Samama MM, Schellong SM, Tapson VF, Turpie AG, Yusen RD, Nicol P, Domenger C, Chen M, Salette G, Deslandes B, Mazzei JA, Casey M, del Carmen Gallo M, Ceresetto J, Grand B, Salem H, Denaro C, Ayyar V, Brighton T, Narayan K, Gibbs H, Gan E, Gallus A, Dunkley S, Chong B, Baker R, Leahy M, Hahn U, Blombery P, Ward C, McGrath B, Prosser I, Chunilal S, Patsch J, Jud M, Aigner K, Hoppichler F, Pall H, Grabher P, Kobierski P, Zwick H, Juchum M, Röger MG, Schönherr HR, Schmalzl F, Geyer C, Kohler B, Delcroix M, Vandewoude M, Wautrecht JC, De Boeck K, Hermans C, Hainaut P, Reis G, Barreto AC, de Arruda Martins M, Carvalho C, Tadini V, de Barros JA, Moura A, Lopes AC, Pereira da Cunha C, Gun C, Milani R, Kahn S, Miron MJ, Demers C, Desjardins L, Lai K, Solymoss S, Rolf JD, Audet R, Turpie AG, Wong T, Kirouac I, Duffy P, Dolan S, Kassis J, Anderson D, Kuchtaruk A, Berlingieri J, Gamble G, Grewal K, Weigel M, Biem J, Labonte R, Cheung A, Forster A, Panju A, Villeneuve J, McCarron B, PachecoF PM, Cuervo F, Dennis R, Londoño A, Ruize EJ, Velásquez JC, Acero R, Vargas RD, Largo U, Mottier D, Proust A, Quere I, Decousus H, Lorcerie B, Bergmann JF, Leduc JJ, Series C, Dien G, Duhamel E, Berrut G, Prazuck T, Goralski M, Hatron JY, Farge D, Jego P, Achkar A, Lacroix P, Doucet J, Bouchard O, Parent F, Boccalon H, Conri C, Le Moigne E, Letellier P, Sanchez O, Zuck P, Harenberg J, Sternkopf M, Lawall H, Kelbel C, Pöhlmann G, Dorsel T, Altmann O, Sehnert W, Vossbeck G, Odemar F, Oettler W, Hartmann A, Nogai K, Bechtold H, Fünfstück R, Omran H, Ittel T, Egger R, Horacek T, Cailloud J, Maier S, Hasenfuss G, Schmidt-Lucke A, Pfisterer M, Lengfelder W, Treib J, Dieckmann HJ, Thomas H, Ziegler T, Brachmann J, Dumoulin FL, Cieslinski G, Schmidt B, Schellong S, Mehta P, Asokan K, Sathe PM, Ramanathan RM, Subbalaxmi MV, Udwadia Z, Sharma SK, Ramakrishnan N, Vigg A, Shlomo Berliner A, Lugassy G, Ellis M, Brenner B, De Gaudenzi E, Imberti D, Silingardi M, Siragusa S, Cimminiello C, Prandoni P, Ageno W, Scannapieco G, Zanatta N, Pini M, Testa S, Lusiani L, PolaF P, Marchegiani G, Patrassi GM, Rodriguez-Gonzalez D, Chavarria-Martinez U, Velasco-Rodriguez JF, Jaimes-Hernandez J, Cruz-Diaz A, Aguilera-Almazan F, Arauz Góngora A, Poblano-Morales M, Velasco-Sanchez G, Quesada-Sanchez A, Lara-Badillo R, Mireles-Munoz A, Borja-Sanchez V, Torbicki A, Psuja P, Pruszczyk P, Musial J, Opolski G, DluzniewskiF M, Zawilska K, Lyusov VA, Gordeev I, Dovgalevskiy PY, Fitilev SB, GlezerF MG, Storozhakov GI, Karpenko MA, Sobolev KE, Khrustalev OA, Chuchalin AG, Vertkin AL, Rumyantseva SA, Belousov UB, Zateytshikov DA, Piradov MA, Verster J, Engelbrecht J, Maritz F, van Zyl L, Latiff GH, De Vries Basson MM, Monreal M, Luis Rodriguez J, Jimenez D, Moreno J, Ramon Calabuig J, Suarez C, Castro A, Reus S, Falga C, Otero R, Aburto M, Conthe P, Page A, Blanco A, Valencia A, Martos F, Ruiz Galiana J, Trujillo J, Boujelben F, Hassine R, Bahri F, Derbel A, Ben Youssef Zouari S, Othmani S, Charfi R, Chakroun M, Bouacha H, Marouane M, Mahjoub S, Miladi R, Laouani Kechrid C, Belkhiria N, Drissa H, Houman H, Cohen A, Gormley M, Moriarty AJ, Rodriguez W, Updegrove J, Hazelrigg S, Etezadi S, Amin D, Krell K, Nadar V, YusenF R, Dexter J, Fei R, Marinelli A, Seibert A, Welker J, O'Riordan W, Kolettis E, Kett D, Hill D, Buchan D, Morris T, Siegel M, Spyropoulos A, Lerner R, Leeds W, Anderson M 3rd, Banish D, Anderson J, Messina F, Baker A, Emdur L, Robinson V, Danisa K, Sangani B, Lawler D, Betzu R, Gatien L, Berlin H, Deichmann R, Kaatz S, Amin M, Fleming H, McKenzie W, Lawton C, Quaranta AJ, Shah A, Rush M, Snyder R, Shriver R, AnsellF J, Tapson V, Touchon RC, Chow RT, Thawani H, Simon SJ, Deitelzweig S, McLafferty R, Jacobson S, Davidson B, Elliott-Mullens R, Patel P, Waters M, HansbroughF J, Abramson N, Lahiri B, El Shahawy M, Levine R, Fenton J, Pendergast WJ, Lavender R, Watson-Ramirez KL, Pollack C, Chamacho B, Albertson T, Beard D, Rehem JR, Elias D, Pistoria M, Chandarana H, Elamin E, Miller W, Anderson CL, Leeper K, Schlau A, Sotolongo C, Karunartne H, Walters GL, Summer W, Faulk LC, Barr L, Thet L, Hite RD, Ost D, Criner G, Martin G, Kaboli P, Brofman D, Johnson J, Rink L, MerliF G, Kendrick L, Schuyler G, Chardon D, Joseph MC, Francis C, Lewinstein C, Mauger S, El-Solh A, Yu H, Green D, Padove S, Sippel J, Norwood P, Haught H, Palmer C, Moncure M, Sturm PW, Gupta AK, Lee T, Ali R, Desbiens N, Witt J, Greenspon L, Heiselman D.

Abstract

BACKGROUND:

Extended-duration low-molecular-weight heparin has been shown to prevent venous thromboembolism (VTE) in high-risk surgical patients.

OBJECTIVE:

To evaluate the efficacy and safety of extended-duration enoxaparin thromboprophylaxis in acutely ill medical patients.

DESIGN:

Randomized, parallel, placebo-controlled trial. Randomization was computer-generated. Allocation was centralized. Patients, caregivers, and outcome assessors were blinded to group assignment. (ClinicalTrials.gov registration number: NCT00077753) SETTING: 370 sites in 20 countries across North and South America, Europe, and Asia.

PATIENTS:

Acutely ill medical patients 40 years or older with recently reduced mobility (bed rest or sedentary without [level 1] or with [level 2] bathroom privileges). Eligibility criteria for patients with level 2 immobility were amended to include only those who had additional VTE risk factors (age >75 years, history of VTE, or active or previous cancer) after interim analyses suggested lower-than-expected VTE rates.

INTERVENTION:

Enoxaparin, 40 mg/d subcutaneously (2975 patients), or placebo (2988 patients), for 28 +/- 4 days after receiving open-label enoxaparin for an initial 10 +/- 4 days.

MEASUREMENTS:

Incidence of VTE up to day 28 and of major bleeding events up to 48 hours after the last study treatment dose.

RESULTS:

Extended-duration enoxaparin reduced VTE incidence compared with placebo (2.5% vs. 4%; absolute risk difference favoring enoxaparin, -1.53% [95.8% CI, -2.54% to -0.52%]). Enoxaparin increased major bleeding events (0.8% vs. 0.3%; absolute risk difference favoring placebo, 0.51% [95% CI, 0.12% to 0.89%]). The benefits of extended-duration enoxaparin seemed to be restricted to women, patients older than 75 years, and those with level 1 immobility.

LIMITATION:

Estimates of efficacy and safety for the overall trial population are difficult to interpret because of the change in eligibility criteria during the trial.

CONCLUSION:

Use of extended-duration enoxaparin reduces VTE more than it increases major bleeding events in acutely ill medical patients with level 1 immobility, those older than 75 years, and women.

PRIMARY FUNDING SOURCE:

Sanofi-aventis.

PMID:
20621900
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk